AIP Arteris, Inc. Insider Trading

Director Saiyed Atiq Raza sold 70.0K shares at blended average of $36.02 in 2 transactions via scheduled 10b5-1 plan

Saiyed Atiq Raza (Director) executed 2 separate sales totaling 70,000 shares for $2,521,103.16 as part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, reducing his holdings from 210,000 to 140,000 shares (-33.3%). The transactions were scheduled, not discretionary. At Arteris, Inc.'s fundamentals show the company generated $22.9M in quarterly revenue with $-8.0M net income, and was unprofitable over the most recent full fiscal year. The stock's 30-day return of +29.8% and 90-day return of +140.8% show strong recent appreciation. His prior 5 trades at this ticker have exhibited mixed post-transaction outcomes (ranging from +2.0% to +57.7% in 30-day windows, and +32.1% to +123.0% in 90-day windows), with no clear directional signal. Since this sale is governed by a pre-arranged plan, the timing and sequencing reflect the plan's schedule rather than a discretionary market signal.

Director Wayne C Cantwell sold 38.5K shares of AIP at $37.23 for $1.4M; retains 189.7K shares after -16.9% reduction

Director Cantwell sold 38,500 shares at $37.23, reducing his stake by -16.9% from 228,198 to 189,698 shares. The company posted a net loss of $-7,959,000.00 in the latest quarter despite annual revenue growth of +22.3%, indicating profitability challenges amid expansion. The stock has rallied +38.9% over 30 days and +114.5% over 90 days, yet remains -4.0% from its 52-week high of $38.47. A director's material reduction of holdings against a backdrop of quarterly losses and strong recent momentum warrants attention to whether this reflects directional concerns about near-term valuation or operational headwinds.

CFO Hawkins sold 221,035 shares for $7,381,777.01 in 5 separate transactions on 2026-05-15, reducing holdings by -66.7%

Nicholas B. Hawkins, VP and Chief Financial Officer, executed 5 separate sales on 2026-05-15 totaling 221,035 shares for $7,381,777.01, reducing his holdings from 331,635 shares to 110,600 shares (a net change of -66.7% vs pre-transaction holdings). The sales occurred at prices ranging from $0.56 to $34.58, with the largest single transaction being 164,916 shares at $33.51 for $5,526,120.77. The company is unprofitable with net income of $-7,959,000.00 in the latest quarter, though annual revenue growth stands at +22.3%. The stock has appreciated +66.1% over 30 days and +130.6% over 90 days, currently trading at $33.71, which is -12.4% from the 52-week high of $38.47.

Director Viana Antonio J sells 40,000 shares at $36.17 avg ($1.4M) under pre-arranged 10b5-1 plan at AIP

Director Viana Antonio J executed a scheduled 40,000-share sale totaling $1,446,963.38 across three tranches on 2026-05-13 and 2026-05-14 under a pre-arranged 10b5-1 trading plan adopted on 2025-06-10. The blended transaction price of $36.17 reflects sales occurring near the 52-week high, with the current price at $37.34 representing only a 3.2% premium above the execution price. Because this sale is part of a predetermined trading schedule rather than discretionary action, it reflects prior planning rather than current conviction or market-timing judgment. The director retains 64,620 shares post-transaction, indicating a substantial continued ownership stake in an unprofitable company ($-8.0M net income) that has achieved strong recent revenue growth of +22.3% year-over-year.

Arteris CEO K Charles Janac sells ~70K shares worth $2.2M; 92nd open-market sale in 36 months with consistent poor timing on prior exits.

K Charles Janac, Arteris's President and CEO, sold a substantial block of shares at a time when the stock is trading at its 52-week high and has rallied sharply in recent months. This is the 92nd open-market sale Janac has executed in the trailing 36 months—an extraordinary volume of dispositions with zero open-market purchases in that window. More concerning, every prior sale at this ticker has been poorly timed: the stock rose in the period following each of his five most recent exits, suggesting a consistent pattern of leaving money on the table. The company itself remains unprofitable on an annual basis with losses widening in the latest quarter, even as revenue grows. For a CEO selling aggressively near the stock's highs without any offsetting buys, the relentless and ineffective timing on his prior exits raises questions about whether this latest sale is driven by genuine conviction about valuation or simply an habitual execution of a preset divestment plan indifferent to price.

10% owner LLC Bayview Legacy sold 70,000 shares of Arteris for ~$2.2M, continuing a pattern of repeated sales.

LLC Bayview Legacy, a significant institutional holder with over ten percent beneficial ownership in Arteris, completed its 18th open-market sale in the past three years, disposing of 70,000 shares. This latest transaction represents continued portfolio activity at a time when the stock has rallied sharply and now trades at its 52-week high—a period that has typically preceded flat or declining performance in this holder's prior exits. Reviewing the fund's recent selling history at Arteris shows mixed timing: two of its four prior sales at this ticker were well-timed exits that preceded declines, while the other two saw the stock rise afterward. The company itself remains unprofitable despite revenue growth, trading at a valuation that reflects significant losses; Arteris is burning cash and has yet to reach breakeven. For a passive institutional holder managing a large block, rotating out shares at elevated prices is routine portfolio management rather than a contrarian bet. The real test will be whether the stock's recent momentum persists or reverts—a question this filing alone does not answer, but one that the holder may be hedging by taking profits at current levels.

Director Raza Saiyed Atiq sells roughly one-third of holdings at stock's 52-week peak

Raza Saiyed Atiq, a director at Arteris, sold a large block representing about 30% of his total stake while the stock is trading near its 52-week high—a timing that stands out because insider selling at peaks often signals caution about near-term valuation. However, the company's fundamentals complicate the picture: Arteris is unprofitable with substantial recent losses, yet revenue is growing double-digits year-over-year. The stock has surged dramatically over the past three months, which could explain why a director would choose to trim a significant position at current levels rather than hold through a period of strong momentum. This sale alone doesn't constitute a red flag, but it warrants attention in context of the company's ongoing path to profitability and whether other insiders or board members follow suit.